Victory Capital Management Inc. Has $1.44 Million Stock Holdings in ADMA Biologics, Inc. (NASDAQ:ADMA)

Victory Capital Management Inc. decreased its stake in ADMA Biologics, Inc. (NASDAQ:ADMA) by 14.4% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 71,946 shares of the biotechnology company’s stock after selling 12,100 shares during the quarter. Victory Capital Management Inc.’s holdings in ADMA Biologics were worth $1,438,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of the stock. CANADA LIFE ASSURANCE Co raised its holdings in shares of ADMA Biologics by 114.3% during the first quarter. CANADA LIFE ASSURANCE Co now owns 54,049 shares of the biotechnology company’s stock valued at $357,000 after acquiring an additional 28,832 shares during the period. Shell Asset Management Co. purchased a new stake in ADMA Biologics in the 1st quarter worth about $155,000. EntryPoint Capital LLC acquired a new stake in ADMA Biologics during the 1st quarter worth about $31,000. 1832 Asset Management L.P. purchased a new position in ADMA Biologics during the 1st quarter valued at about $899,000. Finally, Lazard Asset Management LLC increased its holdings in shares of ADMA Biologics by 5.5% in the 1st quarter. Lazard Asset Management LLC now owns 110,809 shares of the biotechnology company’s stock valued at $730,000 after purchasing an additional 5,731 shares during the period. Hedge funds and other institutional investors own 75.68% of the company’s stock.

ADMA Biologics Trading Up 1.4 %

Shares of NASDAQ:ADMA opened at $21.47 on Tuesday. ADMA Biologics, Inc. has a 1 year low of $3.60 and a 1 year high of $23.64. The firm has a fifty day moving average price of $18.86 and a 200 day moving average price of $14.95. The stock has a market capitalization of $5.08 billion, a PE ratio of 75.64 and a beta of 0.64. The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48.

ADMA Biologics (NASDAQ:ADMA) last issued its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share for the quarter, beating analysts’ consensus estimates of $0.13 by $0.02. ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. The business had revenue of $119.84 million for the quarter, compared to the consensus estimate of $107.25 million. During the same period last year, the business earned $0.01 EPS. Analysts expect that ADMA Biologics, Inc. will post 0.52 EPS for the current fiscal year.

Insider Buying and Selling

In related news, COO Kaitlin M. Kestenberg-Messina sold 24,150 shares of the business’s stock in a transaction on Friday, August 30th. The shares were sold at an average price of $16.90, for a total transaction of $408,135.00. Following the transaction, the chief operating officer now owns 449,088 shares of the company’s stock, valued at approximately $7,589,587.20. The trade was a 5.10 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Jerrold B. Grossman sold 136,861 shares of the stock in a transaction on Thursday, August 29th. The shares were sold at an average price of $17.27, for a total transaction of $2,363,589.47. Following the completion of the sale, the director now directly owns 467,305 shares of the company’s stock, valued at approximately $8,070,357.35. This trade represents a 22.65 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 185,011 shares of company stock worth $3,255,204 in the last quarter. 3.70% of the stock is currently owned by company insiders.

Analyst Ratings Changes

ADMA has been the subject of a number of research analyst reports. Cantor Fitzgerald reiterated an “overweight” rating and issued a $20.00 target price on shares of ADMA Biologics in a research report on Friday, September 20th. HC Wainwright lifted their price objective on ADMA Biologics from $18.00 to $26.00 and gave the company a “buy” rating in a research report on Friday, November 8th. Finally, Raymond James upped their target price on ADMA Biologics from $18.00 to $25.00 and gave the stock a “strong-buy” rating in a research report on Friday, November 8th.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.